Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study

Autor: Eve M.D. Smith, Naomi Egbivwie, Andrea L. Jorgensen, Coziana Ciurtin, Eslam Al-Abadi, Kate Armon, Kathryn Bailey, Mary Brennan, Janet Gardner-Medwin, Kirsty Haslam, Daniel P. Hawley, Alice Leahy, Valentina Leone, Gulshan Malik, Zoe McLaren, Clarissa Pilkington, Athimalaipet V. Ramanan, Satyapal Rangaraj, Annie Ratcliffe, Phil Riley, Ethan Sen, Arani Sridhar, Nick Wilkinson, Fiona Wood, Michael W. Beresford, Christian M. Hedrich
Rok vydání: 2022
Předmět:
Zdroj: Clinical immunology (Orlando, Fla.). 239
ISSN: 1521-7035
1521-6616
Popis: Background:\ud In the absence of clinical trials evidence, Juvenile-onset Systemic Lupus Erythematosus (JSLE) treatment plans vary.\ud \ud Aim:\ud To explore ‘real world’ treatment utilising longitudinal UK JSLE Cohort Study data.\ud \ud Methods:\ud Data collected between 07/2009–05/2020 was used to explore the choice/sequence of immunomodulating drugs from diagnosis. Multivariate logistic regression determined how organ-domain involvement (pBILAG-2004) impacted treatment choice.\ud \ud Result:\ud 349 patients met inclusion criteria, median follow-up 4-years (IQR:2,6). Mycophenolate mofetil (MMF) was most commonly used for the majority of organ-domains, and significantly associated with renal involvement (OR:1.99, 95% CI:1.65–2.41, pc < 0.01). Analyses assessing the sequence of immunomodulators focused on 197/349 patients (meeting relevant inclusion/exclusion criteria). 10/197 (5%) solely recieved hydroxychloroquine/prednisolone, 62/197 (31%) received a single-immunomodulator, 69/197 (36%) received two, and 36/197 patients (28%) received ≥three immunomodulators. The most common first and second line immunomodulator was MMF. Rituximab was the most common third-line immunomodulator.\ud \ud Conclusions:\ud Most UK JSLE patients required ≥two immunomodulators, with MMF used most commonly.
Databáze: OpenAIRE
Externí odkaz: